Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04661514

Organisation Name: University of California, San Diego

Overal Status: Recruiting

Start Date: May 1, 2021

Last Update: June 4, 2021

Lead Sponsor: University of California, San Diego

Brief Summary: The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.

Conditions:
  • Anorexia Nervosa


Total execution time in seconds: 0.18316912651062